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Abstract Human stromal (mesenchymal) stem cells (hMSCs)
are multipotent stem cells with ability to differentiate into
mesoderm-type cells e.g. osteoblasts and adipocytes and thus
they are being introduced into clinical trials for tissue regener-
ation. Traditionally, hMSCs have been isolated from bone
marrow, but the number of cells obtained is limited. Here, we
compared the MSC-like cell populations, obtained from alter-
native sources for MSC: adipose tissue and skin, with the
standard phenotype of human bonemarrowMSC (BM-MSCs).
MSC from human adipose tissue (human adipose stromal cells
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(hATSCs)) and human skin (human adult skin stromal cells,
(hASSCs) and human new-born skin stromal cells (hNSSCs))
grew readily in culture and the growth rate was highest in
hNSSCs and lowest in hATSCs. Compared with phenotype
of hBM-MSC, all cell populations were CD34−, CD45−,
CD14−, CD31−, HLA-DR−, CD13+, CD29+, CD44+, CD73+,
CD90+,and CD105+. When exposed to in vitro differentiation,
hATSCs, hASSCs and hNSSCs exhibited quantitative differ-
ences in their ability to differentiate into adipocytes and to
osteoblastic cells. Using a microarray-based approach we have
unveiled a common MSC molecular signature composed of 33
CD markers including known MSC markers and several novel
markers e.g. CD165, CD276, and CD82. However, significant
differences in the molecular phenotype between these different
stromal cell populations were observed suggesting ontological
and functional differences. In conclusion, MSC populations
obtained from different tissues exhibit significant differences
in their proliferation, differentiation and molecular phenotype,
which should be taken into consideration when planning their
use in clinical protocols.
Keywords Stromal cells .Mesenchymal stem cell . Adipose
tissue . Bone marrow . Skin . DNAmicroarray
Introduction
Human stromal stem cells (also known as mesenchymal
stem cells or multipotent stromal stem cells) (hMSC) are a
group of clonogenic cells capable of self-renewal and multi-
lineage differentiation into mesoderm-type cells e.g. osteo-
blasts, adipocytes and chondrocytes [1, 2]. MSC are being
introduced in a number of clinical trials for tissue repair e.g.
bone and cartilage defects, for the enhancement of tissue
regeneration e.g. myocardial infarction, and immune modu-
lation e.g. graft-versus-host disease (GvHD) [1, 3]. The
initial results from these trials are very encouraging. The
standard site for obtaining human MSC is bone marrow
where the cells are located on the abluminal surface of blood
vessels [4]. However, one limitation for obtaining hMSC
from bone marrow is the difficulty of obtaining enough
number of cells required for clinical studies [5]. During the
recent years, MSC-like populations have been obtained
from a wide range of tissues e.g. adipose tissue [6], skin
[7], blood [8], umblical cord blood [9], teeth [10], pancreas
[11] and liver [12]. Among all these tissues, adipose tissue
and skin are attractive choices to obtain cells needed for
clinical studies due to the ease of obtaining clinical samples.
Adipose tissue used for providing MSC is usually
obtained during operative procedure e.g. liposuction [13]
and human adipose tissue derived stromal cells (hATSCs)
have been reported to exhibit a similar phenotype to that of
human bone marrow MSC (hBM-MSCs) [6, 13] . Also
recently, it has been reported that stromal cultures of fore-
skin and skin can generate MSC-like cells with differentia-
tion capacity into mesodermal cells (adipocytes, osteoblasts,
chondrocytes) and possibly to cells from the ectodermal
cells and endodermal lineages in vitro [14–16]. However,
similarities and differences of these different cell popula-
tions are not clearly defined.
The aim of the present study was to compare stromal cell
populations obtained from two clinically relevant sources:
adipose tissue and skin with the standard bone marrow-
derived MSC. In addition, we employed microarray-based
gene expression profiling in order to compare the molecular
phenotype of these cell populations.
Material and Methods
Cell Culture
We obtained samples of adipose tissue and dermal skin from
patients undergoing abdominal bariatric surgery, lipectomy,
knee replacement or gastrointestinal operations. Fresh fore-
skin specimens were obtained from 2–3 day old male
babies. None of the patients had malignant disease and all
provided written informed consent. The project was ap-
proved by the Institution Review Board of King Saud Uni-
versity Medical College and Hospital (10-2815-IRB).
Unless otherwise stated, the basal culture medium used in
all experiments is Dulbecco’s Modified Eagle Medium
(DMEM) (supplemented with D-glucose 4500 mg/L,
4 mM L-Glutamine and 110 mg/L Sodium Pyruvate, 10 %),
Fetal Bovine Serum (FBS) (10 %), Penicillin-Streptomycin(P/
S) (1 %) and non-essential amino acids (1 %). All reagents
were purchased from Gibco-Invitrogen, USA.
Human Adipose-Tissue Stromal Cells (hATSCs)
The adipose tissues were washed 3 to 4 times using Phosphate
buffered saline (PBS), minced and incubated in 1 % collage-
nase type 1 for 45 min at 37 °C. Mature adipocytes and
undigested tissue fragments were separated from pellets of
stromal vascular fraction (SVF) by centrifugation at 500 g for
15 min. SVF cells were re-suspended in culture medium and
plated in 25 cm2 tissue culture flasks and maintained in a
humidified incubator at 37 °C and 5 % CO2. All non-adherent
cells were removed after 24 h. Cells were fed with newmedium
for every 3–4 days until 70–80 % confluence. For all experi-
ments cells were used at passage 4 with division ratio 1:3.
Human Skin Stromal Cells
Skin stromal cells were derived from two sources: foreskin
samples (human new-born skin stromal cells, hNSSCs) and
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from abdominal or knee skin samples (human adult skin
stromal cells, hASSCs). The skin specimens were washed in
PBS and the subcutaneous tissues (hypodermis) were me-
chanically dissected and removed. The samples were cut
into small pieces ≈3 mm and employed as an explant culture
with the dermis layer lying on the culture surface. The
tissues were maintained in a humidified incubator at 37 °C
and 5 % CO2. For all experiments cells were used at passage
4 with division ratio 1:3. For DNA microarray studies, two
commercially available non-stem fibroblastic cell lines were
included: neonatal foreskin fibroblasts HFF1(ATCC #
SCRC-1041) and BJ (ATCC # SCRC-2522).
Human Bone Marrow-Derived MSC
As a model for human bone marrow derived MSC
(hBM-MSCs), we employed a well characterized hMSC
cell line that has been telomerized by the human telo-
merase reversetranscriptase gene (hTERT) transduction
and known as hMSC-TERT [17]. The hMSC-TERT ex-
press all known markers and similar differentiation ca-
pacity of normal hBM-MSCs in vitro and in vivo [18].
For the DNA microarray studies, we included as a con-
trol, primary bone marrow derived MSC that were
obtained from haematologically normal, osteoarthritic do-
nor patients undergoing routine total hip-replacement sur-
gery using STRO-1 antibody by immune magnetic
panning (Kindly provided by Dr Emmajayne Kingham
and Professor Richard Oreffo, University of Southamp-
ton, UK) .
Cell Proliferation
Proliferation rates of hATSCs, hASSCs and hNSSCs were
determined by counting cell number and calculating popu-
lation doubling (PD) rate. The cells were cultured in 6 cm2
tissue culture petri dish at cell density 8000 cells/cm2. At
confluency, the cells were trypsinized and counted manually
by hemocytometer. At each passage, population doubling
was determined by the formula: logN/log2 where N is the
number of cells at confluence divided by the initial cell
number. Cumulative PD level is the sum of population
doublings and PD rate is PD/time in culture.
Colony Forming Unit-Fibroblast (CFU-F) Assay
hATSCs, hASSCs and hNSSCs were plated at 103 cells in
6-cm petri dishes and allowed to grow for 15 days. The
cultures were terminated and stained with crystal violet for
colony visualization. A colony was defined as a group of
cells (>40). The colonies were counted manually under an
inverted microscope.
Cell Differentiation
Osteoblast Differentiation
Cells were cultured in basal medium till 70–80 % conflu-
ence. Osteogenic induction medium composed of DMEM
containing 10 % FBS, 1 % P/S, 50 μg/mL L-ascorbic acid
(Wako Chemicals GmbH, Neuss, Germany), 10 mM β-
glycerophosphate (Sigma), and 10 nM calcitriol[(1α,25-
dihydroxy vitamin D3) (sigma)], 10 nM dexamethasone
(Sigma) was added and was changed every 3 days. Control
cultures were maintained in vehicle-containing basal
medium.
Adipocyte Differentiation
Cells were cultured in basal medium until 90–100 %
confluence and then transferred to DMEM medium con-
taining adipogenic-induction mixture containing 10 %
FBS, 10 % Horse Serum (Sigma), 1 % P/S, 100 nM
dexamethasone, 0.45 mM isobutyl methyl xanthine [(IBMX)
(Sigma)], 3 μg/mL insulin (Sigma), and 1 μM Rosiglitazone
[(BRL49653) (Novo Nordisk, Bagsvaerd, Denmark)]. The
adipogenic inductionmediumwas replaced every 3 days. Con-
trol cells were cultured in vehicle-containing basal medium.
Cytochemical Assays
Alkaline Phosphatase (ALP) Staining for Osteoblasts
Cells were washed in PBS, fixed in acetone/citrate buffer
and incubated with ALP substrate solution (naphthol AS-TR
phosphate 0.1M Tris buffer, pH 9.0) for 1 h at room
temperature.
Oil Red-O Staining for Adipocytes
Cells were washed in PBS, fixed in 4 % formaldehyde and
stained for 1 h at room temperature with filtered Oil red-O
staining solution (prepared by dissolving 0.5 g Oil red-O
powder in 60 % isopropanol).
Immunofluorescence Staining
Cells were fixed with 4 % cold paraformaldehyde (Sigma)
for 15 min and permeabilized with 0.1 % Triton X-100
(Sigma) for 10 min. After washing with PBS, cells were
treated with 3 % bovine serum albumin (BSA, Sigma) for
30 min, followed by incubation with primary antibody (pu-
rified mouse anti-vimentin, BD Pharminogen) diluted in
PBS (1:100) at 4 °C overnight. After removal of primary
antibodies, cells were washed three times with PBS, and the
secondary antibody (Goat polyclonal to anti mouse IgG,
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Abcam) conjugated to FITCwas added (1:4000) and incubated
for 1 h at room temperature. Cells were washed three times
with PBS, and mounted with a medium containing DAPI to
detect nuclei (VectaShield; Vector Labs, Burlingame, CA).
Flow Cytometry (FACS) Analysis
Cells were harvested by use of 0.05 % trypsin-EDTA for
5 min at 37 °C, recovered by centrifugation at 200 g for
5 min, washed twice in ice-cold PBS supplemented with
2 % FBS and re-suspended at a concentration of 105 cells/
antibody test. Ten μL of PE-conjugated mouse anti-human
CD146, CD73, CD29 and HLA-DR, FITC-conjugated
mouse anti-human CD34, CD90, CD45, CD13 and CD31,
APC-conjugated mouse anti-human CD105, CD14 and
CD44 antibodies (all from BD Biosciences, except that the
monoclonal antibody against human CD105, was from
R&D systems) were used. Negative control staining was
performed using a FITC/PE/APC-conjugated mouse IgG1
isotype antibodies. After storage for 30 min at room tem-
perature in the dark, cells were washed with PBS, re-
suspended in 500 μL of PBS and analyzed in the BD FACS
Calibur flow cytometer (BD Biosciences). Living cells were
gated in a dot plot of forward versus side scatter signals
acquired on linear scale. At least, 8000 gated events were
acquired on a log fluorescence scale. Positive staining was
distinct as the emission of a fluorescence signal that sur-
passed levels achieved by >99 % of control cell population
stained with corresponding isotype antibodies. The ratios of
fluorescence signals versus scatter signals were calculated
and histograms were generated using the software Cell
Quest Pro Software Version 3.3 (BD Biosciences).
Reverse Transcriptase (RT)-Real-Time Quantitative
Polymerase Chain Reaction (qPCR)
Total RNAwas extracted using MagNA pure compact RNA
isolation kit (Roche Applied Science, Germany. Cat No:
04802993001) in automated MagNA pure compact system
(Roche, Germany). cDNA synthesis and Polymerase chain
reaction (PCR) samples were prepared using a iScript One-
step RT-PCR Kit with SYBER Green (Bio-Rad, USA) and
run on a Light Cycler (Roche) PCR machine. Relative
quantification of PCR products were based on value differ-
ences between the target and β-actin control using the
2−ΔΔCT method., The following RT-PCR primers (all from
Invitrogen limited, UK) were used to detect the expression
of specific ß-actin (forward: TGTGCCCATCTAC
GAGGGGTATGC, reverse: GGTACATGGTGGTGCCGC
CAGACA, amplify 448 bp), ALP (forward: ACGTGGC-
TAAGAATGTCATC , r e v e r s e : CTGGTAGGC
GATGTCCTTA, amplify 475 bp), Osteocalcin (forward:
AGAGCGACACCCTAGAC, reverse: CATGAGAGCCCT
CACA, amplify 310 bp), Osteopontin (forward:
GGTGATGTCCTCGTCTGTA, reverse : CCAAG
TAAGTCCAACGAAAG, amplify 347 bp) PPAR-γ 2 (for-
ward: CTCCACTTTGATTGCACTTTGG, reverse:
TTCTCCTAT TGACCCAGAAAGC, amplify 307 bp),
aP2 (forward: TGGTTGATTTTCCATCCCAT, reverse:
GCCAGGAATTTGACGAAGTC, amplify 107 bp), Adipo-
nectin (forward: ATGTCTCCCTTAGGACCAATAAG, re-
verse: TGTTGCTGGGAGCTGTTCTACTG, amplify
234 bp. The relative abundance of target mRNA was
expressed relative to β-actin gene expression.
Microarray-Based Global Gene Expression Analysis
Total RNA was isolated using the GeneMatrix Universal
RNA Purification Kit (Cat. E 3598-02, Roboklon, Berlin,
Germany) and quality-checked by Nanodrop analysis
(Nanodrop Technologies, Wilmington, DE, USA). 400 ng
of total RNAwas used as input for generating biotin-labeled
cRNA (Ambion, Austin, TX, United States). cRNA samples
were then hybridized onto Illumina human-8 BeadChips
version 3. Hybridizations, washing, Cy3-streptavidin stain-
ing and scanning were performed on the Illumina BeadSta-
tion 500 platform (Illumina, San Diego, CA, USA),
according to the manufacturer’s instruction. hMSC-TERT
was hybridized in duplicates, while triplicates were used for
the following samples: hNSSCs, hASSCs, hATSCs. Expres-
sion data analysis was carried out using the BeadStudio
software 3.0 (Illumina, San Diego, CA, USA). Raw data
were background-subtracted, normalized using the “rank
invariant” algorithm, and filtered for significant expression
on the basis of negative control beads. Genes were considered
significantly expressed with detection p values≤0.01. Differ-
ential expression analysis was performed with the illumina
custom method using hMSC-TERT as reference control. The
following parameters were set to identify statistical signifi-
cance: differential p values≤0.01, fold change ratio >1.5.
Pathway analysis was performed using DAVID Bioinfor-
matics Resources 6.7 (http://david.abcc.ncifcrf.gov). Heatmap
picture was generated using Microarray Software Suite TM4
(TM4.org).
Statistical Analysis
All results are based on at least 3 independent experiments
and are expressed as mean % ± SD for 6 donors in each
group. The One-Way ANOVAwas used to analyze results of
FACS. Post-hoc testing was performed for intergroup com-
parison using student T-test. Student t test was used to
compare the mean values of PD rates between groups. Value
of P<0.05 was considered statistically significant. The
SPSS software package (version 17.0; SPSS Inc., USA)
was used for the statistical testing.
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Results
Cell Morphology
hATSCs, hASSCs and hNSSCs as well as hMSC-TERT
exhibited fibroblast-like appearance with no distinct mor-
phological differences (Supplementary Figure 1). Also, im-
munocytochemical staining for vimentin which a general
marker for mesenchymal cells, demonstrated similar stain-
ing pattern among the four cell populations (Fig. 1b).
FACS Analysis for Surface Marker Expression
hATSCs, hASSCs and hNSSCs and hMSC-TERT were an-
alyzed for expression of CD markers known to be expressed
by MSC (Fig. 1a). All the cell populations were negative for
the hematopoietic and endothelial lineage markers CD34,
CD45, CD14, CD31, as well as for the MHC class II
molecule: HLADR. The cell populations were positive for
known hBM-MSC markers and the percentage of positive
cells were similar in all four cell populations except for
CD146 that was expressed at low levels (5 %) in hATSCs
(Supplementary Table 1).
Cell Proliferation
Individual growth curves of hATSCs, hASSCs and hNSSCs
cell strains and the mean values of growth rate as estimated
by PD/day in each cell type are presented in Figs. 2a & b. As
shown in Fig. 2b, hNSSCs exhibited a higher cell prolifer-
ation rate in long-term cultures compared with hASSCs and
hATSCs as evidenced by mean PD rate of 0.78, 1.13 and
1.11 PD/day, respectively.
CFU-f Formation
hATSCs, hASSCs and hNSSCs were able to form colonies
(supplementary Figure 2) and the number of colonies
formed in hATSCs were lower than those formed in
hASSCs and hNSSCs.
Cell Differentiation
Osteoblast Differentiation
hATSCs, hASSCs, hNSSCs and hMSC-TERTwere exposed
to 21-day in vitro osteoblast differentiation and time course
expression of osteoblastic makers (ALP, osteocalcin and
osteopontin) was determined (Fig. 3). Based on fold in-
crease in expression of osteoblastic markers, induction of
osteoblastic phenotype was most pronounced in hMSC-
TERT. hATSCs, hNSSCs and hASSCs exhibited limited
responses in expression of ALP and osteocalcin. Similar
data were observed from ALP cytochemical staining where
OB-induced hMSC-TERT exhibited the most intense stain-
ing followed by hATSCs and to lesser extent by hASSCs
and hNSSCs (Supplementary Figure 3).
Adipocyte Differentiation
hATSCs, hASSCs and hNSSCs and hMSC-TERT were ex-
posed to 21-day in vitro adipocyte differentiation and time
course expression of adipocytic makers (PPARγ2, aP2 and
adiponectin) was determined (Fig. 3). The four cell popula-
tions responded to adipocyte induction by up-regulation of
adipocytic gene markers. Large inter-individual variation in
the degree of adipogenic responses were observed among
different cell strains obtained from different donors but all
cell population formed lipid-filled adipcoytes. Adipocyte
formation was most extensive in hATSCs (Supplementary
Figure 4).
Microarray Analysis
In order to identify the molecular phenotype of hATSCs,
hASSCs, hNSSCs and hMSC-TERT cells, microarray-based
gene expression was carried out. Hierarchical clustering
(Supplementary Figure 5A, B) and the correlation co-
efficients-R2 (Supplementary Figure 5C) revealed that the
transcriptome of hNSSCs is much closer to that of hMSC-
TERT cells (R2 0.803–0.827), followed by hASSCs (R2
0.774–0.832), and then hATSCs cells (R2 0.641–0.791).
To enable a clear overview of the distinct and overlap-
ping gene expression patterns between these cell popula-
tions, a Venn diagram was constructed based on genes
detected as expressed within each cell type (Fig. 4a). Full
details of these groups of genes and associated pathways are
presented in supplementary Table 2. A vast number of genes
(n06533) are expressed in common in all the cell types, a
distinct feature of this signature is the expression of known
MSC surface markers such as (CD29, CD44, CD73, CD90,
CD63, CD71, CD105, CD304) and the lack of expression of
prototypic hematopoietic antigens such as CD34, CD11a
and CD45 (Table 1). An expanded list of the expression
patterns of various cell surface markers is presented in
Table 1. Most notable is the core expression of 36 cell
surface markers (cluster I) which we refer to as a “common
MSC molecular signature”. This cluster also includes CD29,
CD44, CD73, CD90, CD63, CD71, CD105, CD304. This
cluster is also expressed in primary bone marrow hMSC-
STRO+ cells. Cluster II is composed of genes of cell surface
markers that are not expressed in hMSC-TERT nor in
hMSC-STRO+ including CD34, CD11a and CD45. We
found that 72 out of 82 surface markers (cluster I and II)
reveal the same expression pattern in hMSC-TERT and
hMSC-STRO+. Ten surface markers are expressed in
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hMSC-TERT, hNSSCs, hATSCs and hASSCs but not in
hMSC-STRO+ : cluster III: surface markers CD49b,
CD49d, CD115, CD117, CD164, HLA-DRA. Finally, clus-
ter IV is composed of surface markers CD14, CD15, CD102
Fig. 1 Phenotypic analysis hMSC-TERT, hATSCs, hASSCs and
hNSSCs. The human bone marrow stromal (mesenchymal) stem cell
(hMSC) immortalized with human telomerase reverse transcriptase
gene (hMSC-TERT) and stromal cells derived from adipose tissue
(hATSCs), adult dermal skin (hASSCs) and neonatal foreskin
(hNSSCs) cells were cultured using plastic adherence. a Flow
cytometry analysis of CD cell surface proteins. Filled histograms
represent cells stained with the corresponding isotype control antibody.
Five thousand events were collected and analyzed. b Immunofluores-
cence based detection of Vimentin expression and visualization of
nuclei using DAPI
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which are expressed in hMSC-STRO+, hNSSCs, hATSCs
and hASSCs but not in hMSC-TERT. None of these surface
markers were expressed in HFF and in BJ cell line only
CD104 was expressed.
A distinct set of 601 genes was found to be expressed
exclusively in the MSC-TERT cells, amongst these genes
are BGLAP, CD115/CSF1R, DLX5 and RUNX2. BGLAP
(bone γ-carboxyglutamate (Gla) protein) encodes for osteo-
calcin, whilst DLX5 and RUNX2 are transcription factors
involved in osteoblast differentiation and bone develop-
ment. The hATSCs-specific gene is of 263, includes the cell
surface markers, CD31, CD61 and CD120b, whilst 104 and
111 genes specify the cellular identity of hNSSCs and
hASSCs cells respectively. The corresponding signaling
and metabolic pathways associated with these cell type-
specific gene signatures are presented in supplementary
Table 2. The signaling pathways enriched in hMSC-TERT
included pathways involved in bone formation e.g. Wnt,
TGF-B and MAPK signaling while signaling pathways
enriched in hATSCs belonged to adipocyte-relevant meta-
bolic functions e.g. steroid hormone biosynthesis and Lino-
leic acid metabolism.
Fig. 2 Proliferation potential of hATSCs, hASSCs and hNSSCs. Stro-
mal cells derived from adipose tissue (hATSCs), adult dermal skin
(hASSCs) and neonatal foreskin (hNSSCs) cells were cultured using
plastic adherence. a hATSCs (n07), hASSCs (n05) and hNSSCs
(n06) cumulative population doublings (PD) during long-term culture.
b PD rate of hATSCs, hASSCs and hNSSCs. *p<0.05
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Discussion
In the present study we performed side-by-side comparison
of 4 populations of stromal cells derived from adipose
tissue, skin and bone marrow. While stromal cell popula-
tions can be defined by common set of CD markers, signif-
icant differences exist in the growth rate, differentiation
potential and molecular signature of these cells.
The bona fide hMSC is derived from bone marrow and
generally defined by a set of CD markers and multifunc-
tional differentiation capacity as documented by several
studies [19–21]. Our data corroborate the presence of a
common set of CD markers expressed in stromal cells from
adipose tissue, skin and bone marrow e.g. CD 90, CD73,
CD29, CD44, CD105, CD13 and that MSC are negative for
hemaptopoietic cell markers: CD45, CD34, CD14, and
HLA-DR.
We found differences in the expression of CD146 be-
tween stromal cell populations with low levels of expression
in adipose tissue MSC compared to skin and bone marrow
MSC. CD146 has been identified as a marker for stromal
stem cells (MSC) in bone marrow [4]. CD146 defines a
population of perivascular and subendothelial cells that is
present in different tissues [22]. However, clonal MSC is
also present in CD146- bone marrow stromal cell fractions
and differences between CD146+and CD146- may be related
to variation in their functions [23]
We observed significant differences in the growth rates
between stromal cells from skin and adipose tissue where
hNSSCs exhibited the highest growth rate. These differences
may not reflect compartment specific characteristics but most
probably reflect differences in donor age: newborn versus
adult donors [5]. Alternatively, differences in growth rate
may reflect culture heterogeneity with variable proportion of
Fig. 3 Gene expression of osteoblast and adipocyte markers during in
vitro differentiation of hMSC-TERT, hATSCs, hASSCs and hNSSCs.
The human bone marrow stromal (mesenchymal) stem cells (hMSC)
immortalized with human telomerase reverse transcriptase gene
(hMSC-TERT) and stromal cells derived from adipose tissue
(hATSCs), adult dermal skin (hASSCs) and neonatal foreskin
(hNSSCs) cells were cultured using plastic adherence and exposed to
either osteoblast or adipocyte differentiation medium over a 21 day (D)
period. Gene expression was normalized to beta-ACTIN and was
represented as fold-change of non-induced D0 control cells. hMSC-
TERT, hATSCs, hASSCs and hNSSCs data are shown as mean ± SD of
three donor biological samples from at least two independent experi-
ments. ALP 0 alkaline phosphatase, PPARg2 0 Peroxisome
proliferator-activated receptor gamma2, aP2 0 adipocyte protein 2
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self-renewing versus lineage-committed cells in different stro-
mal cell compartment [24, 25].
Stromal cells from different compartment have been
demonstrated in a large number of studies to differentiate
into cells in the mesodermal lineages e.g. osteoblasts and
adipocytes [6–8, 10–15, 20, 21, 26]. Our results demonstrate
that there exist quantitative differences between different
stromal cells with respect to their differentiation potential.
Bone marrow stromal cells differentiated readily into oste-
oblastic cells and adipose stromal cells into adipocytes. Skin
stromal cells differentiated better to adipocytes than osteo-
blasts. This suggests the presence of a lineage “imprinting”
in different stromal cell compartments that influences the
differentiation potential of MSC [27, 28]. Alternatively, we
have previously demonstrated that MSC cultures are heter-
ogenous and contains populations of pre-osteoblastic and
pre-adipcytic cell populations in bone marrow stromal cul-
tures in addition to the multipotent MSC [24]. The presence
of variable number of these committed pre-osteoblastic vs
pre-adipocytic cell population may be a factor determining
the outcome of in vitro differentiation assays. Further stud-
ies of clonal analysis of MSC from different compartment
are needed to corroborate this hypothesis.
Molecular profiling based on microarray analysis of steady
state gene expression provides insight into the molecular
phenotype of the cells and have been used previously in
defining the identity of a number of stem cells including
MSC and embryonic stem cells [25, 29]. We observed signif-
icant differences in the molecular profiling of stromal cells
from different compartments, which support the presence of
differences in their in vitro growth and differentiation.
Interestingly, we found that the 4 stromal cell populations
share a common CD marker signature that includes known
CD markers of hBM-MSCs. However, this common “public”
signature, although it is widely used by different investigators
to define the cultured MSC phenotype is not predictive for
their in vitro or in vivo behavior [25] and thus cannot be used
prospectively to define the nature of the cultured cells [1].
Interestingly, microarray studies revealed the presence of a
“private” signature that defines the stromal cells of each
compartment and most probably determines their biological
behavior. For examples, bone marrow MSC molecular signa-
ture was enriched in genes involved in genetic pathways
important for bone formation e.g. Wnt and MAPK signaling
whereas hATSCs were enriched for genes involved in fatty
acid metabolism. Further studies are needed for examining the
predictive value of the “private” molecular signature in defin-
ing the biological behavior of MSC. The validity of our
findings is demonstrated by comparing the molecular pheno-
type of cell strains with that of primary cells. We have
employed hMSC-TERT is an immortalized cell line as a
representative model for human bone marrow derived MSC
and due to its stable phenotype. Side-by-side comparsion of
hMSC-TERT with primary hMSC-STRO+revealed greater
similarity between the two cell populations and that they
shared 83 % of the expressed genes including similar surface
marker phenotype (supplementary figure 6). Similarly, we
included two primary fibroblastic cells HFF1 and BJ, which
in spite of their fibroblastic nature lacked the expression of the
core markers of MSC phenotype.
Our findings have relevance in regenerative medicine.
Bone marrow stromal cells have been utilized for their
Fig. 4 Microarray-based gene expression analysis of hMSC-TERT,
hATSCs, hASSCs and hNSSCs. The human bone marrow stromal
(mesenchymal) stem cells (hMSC) immortalized with human telomer-
ase reverse transcriptase gene (hMSC-TERT) and stromal cells isolated
from adipose tissue (hATSCs), adult dermal skin (hASSCs) and
neonatal foreskin (hNSSCs) cells were cultured using plastic adher-
ence. Total RNAwas isolated and microarray analysis was carried out.
a Venn diagram representing distinct and overlapping gene expression
patterns between these cell populations. b Heat-map of a number of
CD markers representing a common MSC molecular signature
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Table 1 A list of the expression patterns of various cell surface
markers expressed in the human bone marrow stromal (mesenchymal)
stem cells (hMSC) immortalized with human telomerase reverse tran-
scriptase gene (hMSC-TERT), non-immortalized hMSCs sorted for the
marker STRO-1 (hMSC-STRO+), stromal cells isolated from adipose
tissue (hATSCs), adult dermal skin (hASSCs) and neonatal foreskin
(hNSSCs) and fibroblasts cell lines HFF and BJ. Cluster I: expressed in
hMSC-TERT and hMSC-STRO+, cluster II: not expressed in hMSC-
TERT and hMSC-STRO+, cluster III: only expressed in hMSC-TERT,
cluster IV: only expressed in hMSC-STRO+. + 0 gene expression
detected, − 0 gene expression was absent
Gene name Marker hMSC-TERT hMSC-STRO+ hATSCs hNSSCs hASSCs HFF BJ Cluster
ALCAM CD166 + + + + + − − I
ANPEP CD13 + + + + + − −
B2M B2M + + + + + − −
CD276 CD276 + + + + + − −
CD44 CD44 + + + + + − −
CD58 CD58 + + + + + − −
CD63 CD63 + + + + + − −
CD82 CD82 + + + + + − −
CD97 CD97 + + + + + − −
CD99 CD99 + + + + + − −
COL1A1 COL1A1 + + + + + − −
COL3A1 COL3A1 + + + + + − −
ENG CD105 + + + + + − −
HLA-A HLA-A + + + + + − −
ICAM3 CD50 + + + + + − −
IFNGR1 CD119 + + + + + − −
IL1R1 CD121a + + + + + − −
ITGA1 CD49a + + + + + − −
ITGA3 CD49c + + + + + − −
ITGA5 CD49e + + + + + − −
ITGAE CD103 + + + + + − −
ITGAV CD51 + + + + + − −
ITGB1 CD29 + + − + + − −
ITGB2 CD18 + + + − + − −
NCAM1 CD56 + + + + + − −
NRP1 CD304 + + + + + − −
NT5E CD73 + + + + + − −
PDGFRA CD140a + + + + + − −
PVRL2 CD112 + + + + + − −
PVRL3 CD113 + + + + + − −
RUNX2 RUNX2 + + − − − − −
SLC3A2 CD98 + + + + + − −
TFRC CD71 + + + + + − −
THY1 CD90 + + + + + − −
TNFRSF1A CD120a + + + + + − −
VCAM1 CD106 + + + − + − −
BGLAP BGLAP − − − − − − − II
CD109 CD110 − − + + + − −
CD34 CD34 − − − − − − −
CD36 CD36 − − − − − − −
CD38 CD38 − − − − − − −
CD4 CD4 − − − − − − −
CD9 CD9 − − + + + − −
FLT1 FLT2 − − − − − − −
HLA-DRB1 HLA-DRB1 − − − − − − −
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ability for bone tissue replacement and for their immune
modulatory effects. However, our findings suggest that stro-
mal cells from other compartments may not be able to
replace bone marrow stromal cells in clinical protocols due
to the presence of significant differences in their molecular
phenotype and differentiation capacity. Thus, the choice of
cell source should be based on the aim of clinical application
and not on the accessibility of patients’ samples. In this
context, the identification of compartment specific MSC
molecular signature may help in developing a set of
molecular markers that are predictive of the in vivo biolog-
ical behavior of MSC and that can be used in screening of
cultured MSC prior to their clinical use.
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